OTCMKTS:CPHRF

Cipher Pharmaceuticals Competitors

$1.09

+0.03 (+2.83 %)

(As of 04/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.09

Now: $1.09▼

$1.09

50-Day Range

$0.69

MA: $0.89▼

$1.17

52-Week Range

$0.53

Now: $1.09▼

$1.17

Volume505 shs

Average Volume16,166 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying CPHRF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Cipher Pharmaceuticals, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Cipher Pharmaceuticals vs. Abacus Health Products Stock

Abacus Health Products (OTCMKTS:ABAHF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Abacus Health Products and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abacus Health Products	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Abacus Health Products and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abacus Health Products	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Abacus Health Products and Cipher Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abacus Health Products	0	0	0	0	N/A
Cipher Pharmaceuticals	0	1	2	0	2.67

Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Abacus Health Products.

Institutional and Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats Abacus Health Products on 3 of the 3 factors compared between the two stocks.

Cipher Pharmaceuticals vs. Acreage Stock

Acreage (OTCMKTS:ACRGF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Acreage and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acreage	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Acreage and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acreage	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Acreage and Cipher Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acreage	0	1	2	0	2.67
Cipher Pharmaceuticals	0	1	2	0	2.67

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Acreage's higher probable upside, equities analysts plainly believe Acreage is more favorable than Cipher Pharmaceuticals.

Institutional and Insider Ownership

Cipher Pharmaceuticals vs. Applied Biosciences Stock

Applied Biosciences (OTCMKTS:APPB) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Applied Biosciences and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Biosciences	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Applied Biosciences and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Biosciences	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Applied Biosciences and Cipher Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Biosciences	0	0	0	0	N/A
Cipher Pharmaceuticals	0	1	2	0	2.67

Institutional and Insider Ownership

Summary

Cipher Pharmaceuticals beats Applied Biosciences on 3 of the 3 factors compared between the two stocks.

Cipher Pharmaceuticals vs. Ayr Strategies Stock

Ayr Strategies (OTCMKTS:AYRSF) and Cipher Pharmaceuticals (OTCMKTS:CPHRF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Analyst Ratings

This is a summary of recent recommendations for Ayr Strategies and Cipher Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayr Strategies	0	1	6	0	2.86
Cipher Pharmaceuticals	0	1	2	0	2.67

Ayr Strategies currently has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Cipher Pharmaceuticals has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Ayr Strategies.

Institutional and Insider Ownership

Profitability

This table compares Ayr Strategies and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayr Strategies	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Ayr Strategies and Cipher Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayr Strategies	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Cipher Pharmaceuticals vs. Can B Stock

Cipher Pharmaceuticals (OTCMKTS:CPHRF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cipher Pharmaceuticals and Can B, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0	1	2	0	2.67
Can B	0	0	0	0	N/A

Cipher Pharmaceuticals currently has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Given Cipher Pharmaceuticals' higher probable upside, research analysts clearly believe Cipher Pharmaceuticals is more favorable than Can B.

Institutional & Insider Ownership

25.1% of Cipher Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cipher Pharmaceuticals and Can B's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	N/A	N/A	N/A
Can B	N/A	N/A	N/A

Valuation and Earnings

This table compares Cipher Pharmaceuticals and Can B's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Can B	N/A	N/A	N/A	N/A	N/A

Summary

Cipher Pharmaceuticals beats Can B on 3 of the 3 factors compared between the two stocks.

Cipher Pharmaceuticals vs. Cansortium Stock

Cipher Pharmaceuticals (OTCMKTS:CPHRF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Valuation and Earnings

This table compares Cipher Pharmaceuticals and Cansortium's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Cansortium	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Cipher Pharmaceuticals and Cansortium's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	N/A	N/A	N/A
Cansortium	N/A	N/A	N/A

Institutional & Insider Ownership

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cipher Pharmaceuticals and Cansortium, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0	1	2	0	2.67
Cansortium	0	0	1	0	3.00

Cipher Pharmaceuticals currently has a consensus price target of $1.9833, indicating a potential upside of 82.11%. Cansortium has a consensus price target of $1.20, indicating a potential upside of 18.81%. Given Cipher Pharmaceuticals' higher probable upside, research analysts clearly believe Cipher Pharmaceuticals is more favorable than Cansortium.

Summary

Cipher Pharmaceuticals beats Cansortium on 3 of the 4 factors compared between the two stocks.